World-first personalised cancer jab built from a patient's own tumour cuts the risk of melanoma death or return by 42%
About 82% of patients given the jab alongside immunotherapy drug Keytruda were alive and melanoma-free two years on, against 70% on Keytruda alone. The phase three trial of Moderna and MSD's vaccine, intismeran, tracked 1,137 high-risk patients whose tumours had been surgically removed. Each jab is custom-built within weeks using DNA sequencing and artificial intelligence. It is now being tested against lung, kidney and bladder cancer.
Trial leader Prof Georgina Long called the results 'a foundational shift in our approach to cancer'.
The jab uses the same mRNA technology behind Covid vaccines.
Independent experts say longer-term studies are still needed to prove patients live longer.
More
LBCWorld-first personalised cancer jab cuts risk of melanoma returning or death by 42% in major trialThe Independent‘Breakthrough’ cancer jab cuts risk of dying – or the disease coming backDaily MailWorld-first skin cancer vaccine halves deaths from deadly skin cancerThe IndependentWorld’s first mRNA cancer jab for melanoma cuts risk of death by 42%The IndependentWorld-first personalised cancer vaccine slashes risk of death and disease returningBBC News - HealthWorld first personalised cancer vaccine stops disease returning in major trialNY PostFirst-of-its-kind cancer vaccine helps reduce chances of melanoma patients’ tumors returning: studyNYTCancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna ReportThe Guardian‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial showsDaily Mail AUWorld-first cancer vaccine trial slashes death in research by Aussie
